Figure 2.
Management of locally advanced and/or metastatic differentiated cancer or MTC and the criteria for initiation of systemic therapy with kinase inhibitors. RANKL, receptor activator of nuclear factor-кB. [Reprinted by permission from Springer Nature, Hormones & Cancer; Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF inhibitors: experience in thyroid cancer and general review of toxicity. Horm Cancer. 2015;6:21–36.]